VOQUEZNA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Voquezna, and what generic alternatives are available?
Voquezna is a drug marketed by Phathom and is included in three NDAs. There are two patents protecting this drug.
This drug has one hundred and three patent family members in forty-three countries.
The generic ingredient in VOQUEZNA is amoxicillin; clarithromycin; vonoprazan fumarate. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; vonoprazan fumarate profile page.
DrugPatentWatch® Generic Entry Outlook for Voquezna
Voquezna will be eligible for patent challenges on May 3, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 11, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VOQUEZNA?
- What are the global sales for VOQUEZNA?
- What is Average Wholesale Price for VOQUEZNA?
Summary for VOQUEZNA
| International Patents: | 103 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 49 |
| Drug Prices: | Drug price information for VOQUEZNA |
| What excipients (inactive ingredients) are in VOQUEZNA? | VOQUEZNA excipients list |
| DailyMed Link: | VOQUEZNA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VOQUEZNA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for VOQUEZNA
VOQUEZNA is protected by two US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VOQUEZNA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VOQUEZNA
1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting VOQUEZNA
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
USE OF VONOPRAZAN FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE IN ADULTS
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phathom | VOQUEZNA | vonoprazan fumarate | TABLET;ORAL | 215151-001 | Nov 1, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Phathom | VOQUEZNA | vonoprazan fumarate | TABLET;ORAL | 215151-002 | Nov 1, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Phathom | VOQUEZNA | vonoprazan fumarate | TABLET;ORAL | 215151-001 | Nov 1, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Phathom | VOQUEZNA DUAL PAK | amoxicillin; vonoprazan fumarate | CAPSULE, TABLET;ORAL | 215153-001 | May 3, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Phathom | VOQUEZNA | vonoprazan fumarate | TABLET;ORAL | 215151-002 | Nov 1, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VOQUEZNA
When does loss-of-exclusivity occur for VOQUEZNA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2842
Patent: COMPOSICION FARMACEUTICA ESTABILIZADA QUE COMPRENDE UN INGREDIENTE FARMACEUTICAMENTE ACTIVO NO PEPTIDICO
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09277443
Patent: Pharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0916689
Patent: composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 32243
Patent: COMPOSITION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Patent: 36400
Patent: COMPOSITION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 11000170
Patent: Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
Estimated Expiration: ⤷ Sign Up
Patent: 13000224
Patent: Preparacion solida mejorada que comprende un ingrediente farmaceuticamente activo, un plastificante y un acido organico de cadena; metodo para estabilizar una preparacion solida (divisional sol 170-11)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2164581
Patent: Pharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Patent: 2743330
Patent: Pharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Patent: 4784180
Patent: Pharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 90638
Patent: COMPOSICIÓN FARMACÉUTICA
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 110110
Patent: COMPOSICION FARMACEUTICA
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 011000033
Patent: COMPOSICION FARMACEUTICA
Estimated Expiration: ⤷ Sign Up
Patent: 013000172
Patent: COMPOSICION FARMACEUTICA
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 11010855
Patent: COMPOSICIÓN FARMACÉUTICA
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1170272
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
Estimated Expiration: ⤷ Sign Up
Patent: 1201451
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 09985
Patent: COMPOSITION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Patent: 64833
Patent: Composition pharmaceutique stabilisée à la lumière (Photostabilized pharmaceutical composition)
Estimated Expiration: ⤷ Sign Up
Georgia, Republic of
Patent: 0146122
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Patent: 0146166
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 95356
Estimated Expiration: ⤷ Sign Up
Patent: 93363
Estimated Expiration: ⤷ Sign Up
Patent: 11529445
Estimated Expiration: ⤷ Sign Up
Patent: 13047239
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 6305
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Patent: 9461
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 11000757
Patent: COMPOSICION FARMACEUTICA. (PHARMACEUTICAL COMPOSITION.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 556
Patent: تركيب صيدلاني
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 1344
Patent: Stabilized pharmaceutical composition comprising a nonpeptidic active agent
Estimated Expiration: ⤷ Sign Up
Patent: 2592
Patent: Light irradiation resistant pharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 110591
Patent: COMPOSICION FARMACEUTICA ESTABILIZADA A BASE DE UN COMPUESTO NO PEPTIDICO
Estimated Expiration: ⤷ Sign Up
Patent: 140977
Patent: COMPOSICION FARMACEUTICA ESTABILIZADA A BASE DE UN COMPUESTO NO PEPTIDICO
Estimated Expiration: ⤷ Sign Up
Patent: 141585
Patent: COMPOSICION FARMACEUTICA ESTABILIZADA A BASE DE UN COMPUESTO NO PETIDICO
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 6685
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1101198
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 110042334
Patent: PHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 60962
Estimated Expiration: ⤷ Sign Up
Patent: 69592
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 1010992
Patent: Pharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Patent: 1431552
Patent: Pharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 11000030
Patent: PHARACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 3332
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ НЕПЕПТИДНЫЙ АКТИВНЫЙ АГЕНТ С ПЕРВИЧНОЙ ИЛИ ВТОРИЧНОЙ АМИНОГРУППОЙ;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ НЕПЕПТИДНИЙ АКТИВНИЙ АГЕНТ З ПЕРВИННОЮ АБО ВТОРИННОЮ АМІНОГРУПОЮ (PHARMACEUTICAL COMPOSITION CONTAINING A NONPEPTIDIC ACTIVE AGENT HAVING A PRIMARY OR SECONDARY AMINO GROUP)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 008
Patent: COMPOSICIÓN FARMACÉUTICA
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VOQUEZNA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Dominican Republic | P2011000033 | COMPOSICION FARMACEUTICA | ⤷ Sign Up |
| Ecuador | SP11010855 | COMPOSICIÓN FARMACÉUTICA | ⤷ Sign Up |
| Chile | 2013000224 | Preparacion solida mejorada que comprende un ingrediente farmaceuticamente activo, un plastificante y un acido organico de cadena; metodo para estabilizar una preparacion solida (divisional sol 170-11) | ⤷ Sign Up |
| Malaysia | 169461 | PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
| Montenegro | 00610 | 1 -HETEROCIKLILSULFONIL, 2 -AMINOMETIL, 5- (HETERO-) ARIL SUPSTITUISAN 1-H-PIROL DERIVATI KAO INHIBITORI LUČENJA KISELINE (1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
